Clinical Research Directory

Inclusion Criteria: * Confirmed diagnosis of MPS IIIA * Patient who: 1. Group 1: Received rebisufligene etisparvovec in a prior interventional clinical trial. May be enrolled upon completion of Study ABT-001 (Cohort 4) or end of study (EOS) or early termination (ET) visit from the prior clinical trial (Study ABT-003 or Study LTFU-ABO-102). OR 2. Group 2: Received (or plans to receive) rebisufligene etisparvovec in a postmarketing setting. * Provide informed consent after the nature of the study has been explained, and prior to any research-related procedures. If a minor or an adult with cognitive limitations, willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related procedures. Exclusion Criteria: * Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results.